Issue 43 - Nov 13, 2020
  • News Analysis

    Joe Biden has an unparalleled grasp of the science and politics of cancer

    For the first time in U.S. history, the White House will soon be occupied by a president who has demonstrated a deep understanding of cancer research.

  • Guest Editorial

    A Biden-Harris administration will help sustain our momentum in the fight against cancer

    The recent historic election of President-elect Joe Biden and Vice President-elect Kamala Harris provides an exciting opportunity for the cancer research and medical science communities during the next four years to dramatically improve the health of our nation and the world.

  • An Appreciation

    David A. Ahlquist, pioneer of cancer screening, dies at 69

    With unwavering positivity and unquenchable curiosity, David A. Ahlquist, MD, turned complex challenges into addressable opportunities, and audacious ideas into achievable realities.

  • In Brief

    • Abraham Chachoua named director of Perlmutter Cancer Center’s Lung Cancer Center
    • CWRU and UH Researchers receive $5 million from NCI to investigate relationships between HIV and lung cancer in East Africa
    • John Turchi receives $2.9 million from NCI to improve effectiveness of lung cancer radiation therapy
    • SWOG and The Hope Foundation award two grants designed to give military veterans better access to cancer clinical trials
    • The US Oncology Network enrolls 100,000th patient in the Oncology Care Model
  • TCCL Logo

  • Trials & Tribulations

    #BCSM: Breast cancer social media hashtag gives voice to a community

    When they decided to launch a weekly breast cancer chat on Twitter, all breast cancer survivors and advocates Alicia Staley and Jody Schoger had was a hashtag and a dream.

  • Clinical Roundup

    • Keytruda + Lenvima meet PFS primary endpoint in advanced RCC
    • KEYNOTE-695 study: Tavo + Keytruda demonstrate 30% ORR in anti-PD-1 checkpoint refractory metastatic melanoma
    • State-level lung cancer screening rates are not aligned with lung cancer burden in the U.S.
    • Diagnostic imaging may increase risk of testicular cancer
    • JNCCN study evaluates cost-effectiveness of olaparib for metastatic pancreatic cancer
    • Research detects hormone-upregulated lncRNA within the lymphocyte-specific protein tyrosine kinase discovered in prostate cancer
  • Drugs & Targets

    • FDA approves liquid biopsy NGS companion diagnostic test for multiple cancers and biomarkers
    • FDA issues guidance to enhance diversity in clinical trials, encourage inclusivity in medical product development
    • European Commission approves Opdivo + Yervoy with two cycles of chemotherapy for first-line treatment of metastatic NSCLC
Issue 42 - Nov 6, 2020
Issue 41 - Oct 30, 2020
  • Conversation with The Cancer Letter

    Owkin’s AI model provides proof of concept that machine learning can predict gene expression across cancer types

    Will an oncologist of the not-so-distant future be able to pull up an image of a tumor biopsy slide on a screen and—without having to order a biomarker test—see the molecular characteristics of the cancer?

  • Racism is a malignancy: Ibram X. Kendi reflects on his cancer experience

    After receiving a stage 4 colon cancer diagnosis, author Ibram X. Kendi sought consultation at two hospitals located a mile apart.

  • In Brief

    • AACR 2021 annual meeting will be virtual
    • C. Ola Landgren named the inaugural leader of experimental therapeutics at Sylvester
    • Ingo Mellinghoff named chair of MSK Department of Neurology
    • Beth Gaffney named VP of U.S. and global business development at NCCN
    • Reagan-Udall receives $250,000 from Rockefeller Foundation for COVID-19 Diagnostics Evidence Accelerator
    • Global Cancer Institute extends programs for underserved cancer patients to Bangladesh
  • TCCL Logo

  • Trials & Tribulations

    Toward a new kind of lung cancer awareness: Addressing financial toxicity

    November is Lung Cancer Awareness Month, a time to turn our attention to an issue that already warrants our focus year-round.

  • Clinical Roundup

    • USPSTF draft guideline: Colorectal cancer screening should start at 45
    • Study: Racial disparities in treatment NSCLC persist despite gains
    • Winship study shows increased DFS rates for men with prostate cancer
    • New York Proton Center joins RadComp clinical trial evaluating proton v. photon therapy in non-metastatic breast cancer
  • Drugs & Targets

    • FoundationOne CDx test receives FDA approval as companion diagnostic to identify NTRK fusions in solid tumors for Vitrakvi
    • FDA approves cobas EGFR Mutation Test v2 as the first companion diagnostic test for expanded EGFR TKI therapies in NSCLC
    • CPI-613 receives FDA orphan drug designation for soft tissue sarcoma
    • Exact Sciences to acquire Thrive Earlier Detection
    • EQRx licenses two immune checkpoint inhibitors from CStone Pharmaceuticals.
    • StrataNGS genomic profiling receives Medicare coverage in patients with advanced solid tumors